Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;25(7):936-955.
doi: 10.1002/ejhf.2894. Epub 2023 Jul 17.

Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension

Stefan D Anker  1 , Muhammad Shariq Usman  2 , Markus S Anker  3 , Javed Butler  2   4 , Michael Böhm  5 , William T Abraham  6 , Marianna Adamo  7 , Vijay K Chopra  8 , Mariantonietta Cicoira  9 , Francesco Cosentino  10 , Gerasimos Filippatos  11 , Ewa A Jankowska  12 , Lars H Lund  10 , Brenda Moura  13 , Wilfried Mullens  14 , Burkert Pieske  15 , Piotr Ponikowski  12   16 , Jose R Gonzalez-Juanatey  17 , Amina Rakisheva  18 , Gianluigi Savarese  10 , Petar Seferovic  19 , John R Teerlink  20 , Carsten Tschöpe  1   21 , Maurizio Volterrani  22 , Stephan von Haehling  23 , Jian Zhang  24 , Yuhui Zhang  24 , Johann Bauersachs  25 , Ulf Landmesser  3   26 , Shelley Zieroth  27 , Konstantinos Tsioufis  28 , Antoni Bayes-Genis  29 , Ovidiu Chioncel  30 , Felicita Andreotti  31   32 , Enrico Agabiti-Rosei  33 , Jose L Merino  34 , Marco Metra  7 , Andrew J S Coats  35 , Giuseppe M C Rosano  22
Affiliations
Free article

Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension

Stefan D Anker et al. Eur J Heart Fail. 2023 Jul.
Free article

Abstract

Heart failure with preserved ejection fraction (HFpEF) represents a highly heterogeneous clinical syndrome affected in its development and progression by many comorbidities. The left ventricular diastolic dysfunction may be a manifestation of various combinations of cardiovascular, metabolic, pulmonary, renal, and geriatric conditions. Thus, in addition to treatment with sodium-glucose cotransporter 2 inhibitors in all patients, the most effective method of improving clinical outcomes may be therapy tailored to each patient's clinical profile. To better outline a phenotype-based approach for the treatment of HFpEF, in this joint position paper, the Heart Failure Association of the European Society of Cardiology, the European Heart Rhythm Association and the European Hypertension Society, have developed an algorithm to identify the most common HFpEF phenotypes and identify the evidence-based treatment strategy for each, while taking into account the complexities of multiple comorbidities and polypharmacy.

Keywords: Heart failure; Heart failure with preserved ejection fraction; Phenotype.

PubMed Disclaimer

References

    1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease study 2017. Lancet. 2018;392:1789-1858. https://doi.org/10.1016/S0140-6736(18)32279-7
    1. Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020;22:1342-1356. https://doi.org/10.1002/ejhf.1858
    1. McHugh K, DeVore AD, Wu J, Matsouaka RA, Fonarow GC, Heidenreich PA, et al. Heart failure with preserved ejection fraction and diabetes: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73:602-611. https://doi.org/10.1016/j.jacc.2018.11.033
    1. Murphy SP, Ibrahim NE, Januzzi JL Jr. Heart failure with reduced ejection fraction: A review. JAMA. 2020;324:488-504. https://doi.org/10.1001/jama.2020.10262
    1. Senni M, Greene SJ, Butler J, Fonarow GC, Gheorghiade M. Drug development for heart failure with preserved ejection fraction: What pieces are missing from the puzzle? Can J Cardiol. 2017;33:768-776. https://doi.org/10.1016/j.cjca.2017.03.013

Publication types